Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
more from seeking alpha
Takeover Targets
New: Today, 12:46 AM
Comments (23)
|
+ Follow
« Prev | Next »
10/04 Wall Street Rumors: Our Japan source says, Daiichi Sanko legal department is ready to negotiate with Esperion Therapeutics (ESPR) before the October 16th discovery date, on 10/03 more legal documents show at this time Daiichi has failed to present necessary documents to the court. We had the Case document 1:23-cv-02568 reviewed. It is obvious Daiichi Sankyo Europe $300 million milestone payment agreement was deliberately denied to use a tactic to negotiate a better offer, and more than likely an acquisition offer. Esperion has further milestone agreements between Daiichi and Otsuka totaling $1.5 billion. After careful review, Esperion is completely due the full $300 million milestone payment. Pointed out in the legal document noting the New England Journal of Medicine which reported 23% cardiovascular risk reduction, and entitles Esperion to the full $300 million payment based on the 20% marker agreement, further more Daiichi Sankyo Europe released news on 8/26:
New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease
- Results from a prespecified, secondary analysis of total cardiovascular (CV) events during the CLEAR Outcomes trial demonstrate that bempedoic acid, marketed as NILEMDO®? in Europe, provides a 20% reduction in the risk of total number of serious CV events in high-risk patients, complementing the previously reported 13%* reduction for the primary analysis.1,2
- A separate sub-analysis of the CLEAR Outcomes trial data shows patients with diabetes derive greater absolute benefit from bempedoic acid; furthermore, treatment does not increase HbA1c levels or the incidence of new-onset diabetes.3
- These findings support the benefits of long-term treatment with bempedoic acid to not only lower LDL-C but also reduce the risk for any – first and subsequent – CV events.
More details to come.
from Seeking Alpha
Takeover Targets
New: Today, 7:57 AM
We expect a takeover offer for ESPR given our sources in Japan. WE RIETERATE 9/20/2023 UPDATE: Esperion Therapeutics (ESPR) dispute over $300 million milestone payment, On 9/14 Our source says it is rumored Daiichi Sankyo has been advised to pay Esperion. We have been forwarded this bit of information that says: ?????????????????????????????????????????????????????????????????????????
." We have concluded it would be in Daiichi Sankyo best interest to pay the requested $300 million milestone to Esperion Therapeutics, after careful review of the presented clinical data, the findings presented are favorable to Range of relative risk reduction of 20%, therefore as counsel for Daiichi Sankyo Europe we recommend immediate settlement ". On a separate note: We now have seen information for a several $200+ million loan offers presented to Esperion, these loan offers are non dilutive and have very favorable interest terms and are believed to be tied directly to the $300 million milestone. We are also aware of Form SC 13G filed by MILLENNIUM on 8/29/2023 that shows 2,100,000 shares were bought on the open market at an average $1.70 per share, MILLENNIUM now owns over 5% of Esperion, Institutions now own 87% of Esperion. We believe MILLENNIUM raised its stake this year based on the belief Daiichi Sankyo will settle this year, as does Bank of America analyst. The $300 million payment news would rally the stock price well above $4 a share. It is also very important to note on 8/26/2023 Daiichi Sankyo Europe wrote "Results from a prespecified, secondary analysis of total cardiovascular (CV) events during the CLEAR Outcomes trial demonstrate that bempedoic acid, marketed as NILEMDO®? in Europe, provides a 20% reduction in the risk of total number of serious CV events in high-risk patients, complementing the previously reported 13%* reduction for the primary analysis.1,2" Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
PR & Portfolio Communication Lead, Specialty Medicines
+49 151 1714 7317. Daiichi Sankyo recent released earnings has reported 127% sales growth for Cholesterol drugs licensed from Esperion. We believe Daiichi is going to present Esperion with a BUYOUT offer rather than pay out $1.2 billion. By 2027 Esperion is expected to reach over 5 million patients being prescribed per year and this would generate over $20 billion yearly income. Daiichi Sankyo is now seeing higher prescription sales over PCSK9 inhibitors in Germany as reported by Esperion CEO on his presentation on 9/11/2023 shown on Esperion's website.
Yesterday and today there have been 3 buys of over 200K shares at and around the $1.50 price range.... someone sees something that the market is not seeing. This morning at 9:37 224000 at 1.495 on the ASK of $1.50
ESPR - B of A Securities Upgrades Esperion Therapeutics to Buy, Raises Price Target to $4
June 15, 2023 6:21 AM |
ESPR....................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
I like lamp.
Back to 100 bucks !
And the slow march back to a buck begins.
If you get the weekly scrips please post or message me.
If you haven't listened to the Sept 14th Investors Conference Call, I think it's worth a listen. It's on the Esperion Website: https://morganstanley.webcasts.com/viewer/event.jsp?ei=1362617&tp_key=0d55b82feb
Scripts are outpacing all PCSK9i's compared to the launch of those drugs with virtually NO advertising AND during a Pandemic! PCSK9i's are a billion dollar drug and Nexletol and Nexlezit will make them obsolete before long. CEO Mayleben says as much on the Investor CC.
I think there's a good chance for atleast a 50% gain from these level prior to the end of the year.
Mark this post!
All the best
Keepmecloser and JC - It's good reading your posts. I just took a position here and wonder what you guys think is in store for us. I know that weekly scripts are going to be KEY data in moving this forward. I know from the AMRN board that Tucaman posts weekly scripts. Do you have any idea where he gets them? I would pay a service if I could get them for us.
Okeedohkee let’s try this again ok:
Looking forward to an excellent 4th quarter and good luck to all.
Looking forward to an excellent MONTH for
ESPERION
Just after I posted I realized it was too early so I jumped back in and am looking for the 90 area.
GLTA
Still climbing... my exit target is 65-70
Sold yesterday,up 12 bucks a share not bad.
Buy the dips.
Big day... If things settle down I think I hit the bottom just right on a slew of stocks...
Good Luck... This one has been great on the pullbacks
Great day for all of us longs.
Nope, starting to look better everyday. There will be some bumps in the road though
Not at all.. Always bean a bear here but have made some sells at high prices
No i said that in jest but u know that. I think ESPR is great and hope they have tremendous success with their drugs. Who knows, PFE bought them once, maybe they will buy them again
Well JC?
What do you think,are we still jinxed?
In our opinion....No
I jinxed myself - this will see 60's and 70's again. My wife really likes the data, SD at PFE
Stock has found its bottom we believe and is being supported with little volume.
Good time to buy.
In our opinion
Because Bozo berman is the CEO of DECN and has done nothing but lose money tear over year with scheme after scheme.
This is actually holding up better some other holdings. This could be third time this stock delivers huge returns...
yes, like many others this is a bargain again
We are happy buying @ 36.75 or less...yahooooo
I am still looking for $80 here. Was so close too. Bought at $43 and sold in $70's last yr. My wife told me to buy it at $25 but I didn't listen to her. The first Esperion was sold to PFE (cholesterol to). This is round 2
My wife works for PFE
Great deal in a weak market but when the BigBounce hits it will huge.
Yup. This will be a huge winner
On our way back up.
It’s going to be a good day for E.T. Shareholders!
Yikes Just finished adding 40k more shares..This is a steal IMO
A small correction before a CNN “Higher” high.
GLTA
We believe the stock will continue in the green
Esperion Announces FDA Approval of NEXLETOL(TM) (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
4:38 pm ET February 21, 2020 (Globe Newswire) Print
- First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients -
- NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism -
- Fills an Unmet Need for Affordable Medicines for Millions of Patients with ASCVD or HeFH -
- NEXLETOL will be Commercially Available in the U.S. March 30, 2020 -
- Conference Call and Webcast on Monday, February 24 at 8:00 a.m. Eastern Time -
Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL(TM) (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. NEXLETOL is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for indicated patients.
NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.
"NEXLETOL delivers upon a commitment we've made to millions of patients for a new treatment alternative if they struggle with bad cholesterol and have ASCVD or HeFH," said Tim Mayleben, president and chief executive officer of Esperion. "Even with maximally tolerated statins, which may mean no statin at all, some of these patients can't achieve their LDL-C goals. Today's approval provides them with a new medicine to go along with a healthy diet. We express our sincere gratitude to all of the patients and physicians who put their confidence in Esperion's team of lipid experts."
LDL-C is a waxy, fat-like substance that's found in the body. Elevated LDL-C contributes to a buildup of this fat in the arteries and can lead to cardiovascular events including heart attack and stroke. Despite standard of care treatments, including statin therapy, it is estimated nearly 15 million patients (approximately one in four patients) in the U.S. cannot achieve guideline recommended LDL-C levels.
"The FDA approval of NEXLETOL provides an important option for patients living with elevated LDL-C and ASCVD or increased risk for cardiovascular disease because of HeFH," said Christie M. Ballantyne, M.D., chairman of Esperion's Phase 3 Executive Committee and professor and chief of cardiology at Baylor College of Medicine in Houston. "There are millions of patients who are unable to reach their LDL-C targets despite available medicines. NEXLETOL is the first oral, once-daily, non-statin treatment option for indicated patients in nearly two decades."
The approval of NEXLETOL is supported by a global pivotal Phase 3 LDL-C lowering program conducted in more than 3,000 patients. In these studies, NEXLETOL provided an average of 18 percent placebo corrected LDL-C lowering when used with moderate or high intensity statins. Results from the Phase 3 development program have been published in The New England Journal of Medicine (040 Study), and The Journal of the American Medical Association (047 Study).
NEXLETOL was generally well-tolerated in clinical studies. Label warnings and precautions include hyperuricemia, with the development of gout in a small percentage of patients, as well as increased risk of tendon rupture or injury. Overall in Phase 3 studies, the adverse events reported most frequently in patients who received NEXLETOL were generally reported at similar rates in patients who received placebo. The most common adverse events reported with NEXLETOL (incidence greater-than or equal to 2% and greater than placebo) were upper respiratory tract infections, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. The majority of adverse events reported with NEXLETOL were mild to moderate in severity and balanced in occurrence with adverse events in patients receiving placebo. For additional information on NEXLETOL, please see Full Prescribing Information at Esperion.com.
Today's approval underscores Esperion's commitment to deliver NEXLETOL to adult patients suffering from ASCVD or HeFH and who are unable to reach their LDL-C goal on maximally tolerated statins. Esperion is working with health insurance providers to help ensure broad insurance coverage and patient access to NEXLETOL. Eligible patients with commercial drug insurance coverage for NEXLETOL may pay as little as $10 per fill, up to a 3-month supply. Additionally, Esperion is committed to achieving the lowest branded tier coverage for Medicare patients. Esperion will provide resources to patients whose physician recommends treatment with NEXLETOL. These resources include educational materials, a dedicated call center, as well as a co-pay program for eligible patients.
NEXLETOL will be commercially available in the U.S., by prescription only, on March 30, 2020.
Esperion's second LDL-C lowering medicine, the bempedoic acid / ezetimibe combination tablet, is currently under review by the U.S. FDA; the PDUFA goal date is February 26, 2020.
Conference Call and Webcast Information
Esperion's Lipid Management Team will host a conference call and webcast on Monday, February 24 at 8:00 a.m. Eastern Time to discuss the approval and upcoming commercial launch. The call can be accessed by dialing (877) 312-7508 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the call and providing the access code 4088218. A live audio webcast can be accessed on the investors and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
NEXLETOL(bempedoic acid) Tablet
NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Completed Phase 3 studies conducted in more than 3,000 patients, with over 2,000 patients treated with NEXLETOL, demonstrated an average 18 percent placebo corrected LDL-C lowering when used in patients on moderate or high-intensity statins. NEXLETOL is the first oral, once-daily, non-statin LDL-C lowering medicine approved in the U.S. in nearly 20 years for patients with ASCVD or HeFH. NEXLETOL was approved by the FDA in February 2020.
Indication and Limitation of Use
NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined.
Important Safety Information
-- Warnings and Precautions:
-- Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. The risk for gout events with NEXLETOL was higher in patients with a prior history of gout although gout also occurred more frequently than placebo in patients treated with NEXLETOL who had no prior gout history.
-- Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. The risk for gout events with NEXLETOL was higher in patients with a prior history of gout although gout also occurred more frequently than placebo in patients treated with NEXLETOL who had no prior gout history.
-- Tendon rupture has occurred. Discontinue NEXLETOL at the first sign of tendon rupture. Avoid NEXLETOL in patients who have a history of tendon disorders or tendon rupture.
-- Adverse Reactions:
-- The most common (incidence greater-than or equal to 2% and greater than placebo) adverse reactions are upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia and elevated liver enzymes.
-- The most common (incidence greater-than or equal to 2% and greater than placebo) adverse reactions are upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia and elevated liver enzymes.
-- Drug Interactions:
-- Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.
-- Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.
-- Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Esperion at 833-377-7633 (833 ESPRMED).
CLEAR Cardiovascular Outcomes Trial
The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. Esperion initiated a global cardiovascular outcomes trial (CVOT) to assess the effects of NEXLETOL on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease (CVD) who are only able to tolerate less than the lowest approved daily starting dose of a statin and are considered "statin averse." The CVOT -- known as CLEAR Cardiovascular Outcomes Trial -- is an event-driven, global, randomized, double-blind, placebo-controlled study that completed enrollment in August 2019 of 14,032 patients with hypercholesterolemia and high CVD risk at over 1,400 sites in 32 countries.
Esperion Therapeutics
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc
Esperion Therapeutics' Commitment to Patients with Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading to cardiovascular events, including heart attack or stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C. There are approximately 18 million people in the U.S. with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy -- including individuals considered statin averse -- leaving them at high risk for cardiovascular events. In the United States, more than 50 percent of ASCVD patients who are not able to reach their LDL-C with statins alone need less than a 40 percent reduction to reach their LDL-C threshold.
Esperion's mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide the additional LDL-C lowering that these patients need.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the regulatory approval pathway for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, the therapeutic potential of, and the clinical development plan for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, including Esperion's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies for bempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of the NDAs and the MAAs, and Esperion's expectations for the market for medicines to lower LDL-C, including the commercial launch and market adoption of bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, if approved. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in Esperion's studies, that positive results from a clinical study of bempedoic acid may not be sufficient for EMA approval or necessarily be predictive of the results of future or ongoing clinical studies, that notwithstanding the completion of Esperion's Phase 3 clinical development program for LDL-C lowering, the FDA or EMA require additional development in connection with seeking regulatory approval, or approval of an expanded indication, that existing cash resources may be used more quickly than anticipated, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
References
Investor Contact:
Alex Schwartz
Esperion
734-249-3386
aschwartz@esperion.com
Media Contact:
Ben Church
Esperion
734-864-6774
bchurch@esperion.com
Media Contact:
Elliot Fox
W2Opure
212-257-6724
efox@purecommunications.com
https://ml.globenewswire.com/media/6af55bc4-856a-4007-b242-baeb422ba7e7/small/esperion-logo-primary-png.png
Great news on all media networks!!!!!
Getting close to $80. Think sell half and leave the rest.
20k shares at 39 cost. Should have bought more.
Second trade like this.
Looking to load more into Aeri next
Great action this morning,We are new here,anyone estimate PPS in near future?
Almost there. Think I will wait till 80 target now.
Followers
|
35
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
334
|
Created
|
12/09/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |